KR20200141533A - 항암 조성물 - Google Patents

항암 조성물 Download PDF

Info

Publication number
KR20200141533A
KR20200141533A KR1020207035390A KR20207035390A KR20200141533A KR 20200141533 A KR20200141533 A KR 20200141533A KR 1020207035390 A KR1020207035390 A KR 1020207035390A KR 20207035390 A KR20207035390 A KR 20207035390A KR 20200141533 A KR20200141533 A KR 20200141533A
Authority
KR
South Korea
Prior art keywords
arn
hpmcas
solid dispersion
prostate cancer
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207035390A
Other languages
English (en)
Korean (ko)
Inventor
데니스 마틴 헤스터
제이슨 미카엘 본
Original Assignee
아라곤 파마슈티컬스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52006906&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20200141533(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 아라곤 파마슈티컬스, 인코포레이티드 filed Critical 아라곤 파마슈티컬스, 인코포레이티드
Publication of KR20200141533A publication Critical patent/KR20200141533A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020207035390A 2014-12-05 2015-12-03 항암 조성물 Ceased KR20200141533A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14196594.7 2014-12-05
EP14196594 2014-12-05
PCT/US2015/063661 WO2016090098A1 (en) 2014-12-05 2015-12-03 Anticancer compositions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020177018239A Division KR102348320B1 (ko) 2014-12-05 2015-12-03 항암 조성물

Publications (1)

Publication Number Publication Date
KR20200141533A true KR20200141533A (ko) 2020-12-18

Family

ID=52006906

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207035390A Ceased KR20200141533A (ko) 2014-12-05 2015-12-03 항암 조성물
KR1020177018239A Active KR102348320B1 (ko) 2014-12-05 2015-12-03 항암 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020177018239A Active KR102348320B1 (ko) 2014-12-05 2015-12-03 항암 조성물

Country Status (29)

Country Link
US (3) US20170360754A1 (https=)
EP (2) EP3226841B1 (https=)
JP (2) JP6937692B2 (https=)
KR (2) KR20200141533A (https=)
CN (2) CN106999431B (https=)
AR (1) AR102926A1 (https=)
AU (3) AU2015358490B2 (https=)
BR (1) BR112017011788A2 (https=)
CA (1) CA2969656A1 (https=)
CL (1) CL2017001371A1 (https=)
CO (1) CO2017005572A2 (https=)
CR (1) CR20170216A (https=)
EA (1) EA201791222A1 (https=)
ES (1) ES2996833T3 (https=)
HR (1) HRP20241719T1 (https=)
HU (1) HUE069689T2 (https=)
IL (2) IL252323B (https=)
MA (1) MA41107B1 (https=)
MD (1) MD3226841T2 (https=)
MX (2) MX387933B (https=)
NZ (1) NZ770528A (https=)
PH (1) PH12017500964A1 (https=)
PL (1) PL3226841T3 (https=)
RS (1) RS66323B1 (https=)
SG (1) SG11201704267VA (https=)
SM (1) SMT202400518T1 (https=)
TW (2) TWI754258B (https=)
UA (1) UA120950C2 (https=)
WO (1) WO2016090098A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ744456A (en) 2012-09-26 2019-09-27 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
SG11201704267VA (en) 2014-12-05 2017-06-29 Aragon Pharmaceuticals Inc Anticancer compositions
HUE054935T2 (hu) 2014-12-05 2021-10-28 Aragon Pharmaceuticals Inc Rákellenes készítmények
US10702508B2 (en) 2017-10-16 2020-07-07 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
WO2020144650A1 (en) 2019-01-10 2020-07-16 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of prostate cancer
KR20210122275A (ko) 2019-01-30 2021-10-08 얀센 파마슈티카 엔.브이. 분자 아형에 기초하여 전립선암을 치료하는 방법
EP3917519A1 (en) 2019-01-30 2021-12-08 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
EP3811932A1 (en) 2019-10-22 2021-04-28 Zentiva K.S. Dosage form of apalutamide
US11723898B2 (en) 2019-11-04 2023-08-15 Aragon Pharmaceuticals, Inc. Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment
WO2021245285A1 (en) 2020-06-05 2021-12-09 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
WO2022049523A1 (en) 2020-09-04 2022-03-10 Aragon Pharmaceuticals, Inc. Methods for treating prostate cancer
WO2022195407A1 (en) 2021-03-19 2022-09-22 Aragon Pharmaceuticals, Inc. Methods for treating prostate cancer
WO2023122842A1 (es) * 2021-12-31 2023-07-06 Gador Limitada Proceso para la preparación de apalutamida, intermediarios de sintesis y la dispersion solida amorfa que la contiene
WO2023152611A1 (en) 2022-02-11 2023-08-17 Aragon Pharmaceuticals, Inc. Apalutamide and relugolix for the treatment of prostate cancer
WO2023209555A1 (en) 2022-04-26 2023-11-02 Aragon Pharmaceuticals, Inc. Approved drug products and methods for treating prostate cancer
CN116183787A (zh) * 2022-12-26 2023-05-30 郑州德迈药业有限公司 醋酸羟丙甲纤维素琥珀酸酯在阿帕他胺溶出检测中的应用以及检测方法
CN121038790A (zh) 2023-03-16 2025-11-28 拜耳消费者护理股份有限公司 用于治疗激素敏感性前列腺癌生化复发患者的雄激素受体拮抗剂
WO2025153768A1 (en) * 2024-01-18 2025-07-24 Nanoform Finland Oyj Composition comprising crystalline nanosized apalutamide
WO2025174375A1 (en) * 2024-02-15 2025-08-21 Aragon Pharmaceuticals, Inc. Anticancer compositions
WO2026052846A1 (en) 2024-09-09 2026-03-12 Synthon B.V. Pharmaceutical formulation comprising apalutamide

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2132449C (en) 1992-03-31 2002-09-10 Susan E. Barrie 17 - substituted steroids useful in cancer treatment
ES2287971T3 (es) 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
WO2001060410A1 (en) 2000-02-21 2001-08-23 Takeda Chemical Industries, Ltd. Sustained release preparations of physiologically active compound hardly soluble in water and production process and use of the same
CZ20032225A3 (cs) 2001-02-27 2003-11-12 Astrazeneca Ab Farmaceutická formulace
EP1381358B1 (en) 2001-04-02 2006-05-03 Astrazeneca AB Solid pharmaceutical composition comprising 4'-cyano-trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy-2-methylpropiono- m toluidide and pvp
TNSN03137A1 (en) 2001-06-22 2005-12-23 Pfizer Prod Inc PHARMACEUTICAL COMPOSITIONS COMPRISING LOW SOLUBILITY AND / OR ACID SENSITIVE DRUGS AND NEUTRALIZED ACID POLYMERS.
SE0103424D0 (sv) * 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
BR0307515A (pt) * 2002-02-01 2004-12-07 Pfizer Prod Inc Método para fabricar dispersões de drogas amorfas sólidas secas por aspersão homogêneas usando bicos de pressão
WO2003077827A1 (en) 2002-03-19 2003-09-25 Nippon Shinyaku Co., Ltd. Process for producing drug solid dispersion
AU2003292509B2 (en) 2003-12-15 2007-08-02 Council Of Scientific And Industrial Research Taste masked pharmaceutical compositions comprising bitter drug and pH sensitive polymer
GB0502790D0 (en) 2005-02-10 2005-03-16 Univ London Pharmacy Solid dispersion of hydrophobic bioactive
NZ564223A (en) 2005-05-13 2011-03-31 Univ California Diarylhydantoin compounds for treating hormone refractory prostate cancer
SI2656842T1 (sl) 2006-03-27 2016-10-28 The Regents Of The University Of California Modulator androgenih receptorjev za zdravljenje raka prostate in bolezni, povezanih z androgenimi receptorji
MY172424A (en) 2009-04-03 2019-11-25 Hoffmann La Roche Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof
AU2011218173C1 (en) 2010-02-16 2015-04-16 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
CN102525876B (zh) 2010-12-15 2014-03-12 西安力邦医药科技有限责任公司 阿司匹林固体分散体、其制备方法、药物组合物和用途
WO2012174436A1 (en) 2011-06-15 2012-12-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nuclear receptor modulators and their use for the treatment and prevention of cancer
US20150037407A1 (en) 2012-03-21 2015-02-05 Emphascience, Inc. Method to improve the safety of handling of high potency drugs in solid dosage forms without changing their efficacy
WO2013152342A1 (en) * 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
EP2858985B1 (en) 2012-06-07 2018-04-18 Aragon Pharmaceuticals, Inc. Crystalline forms of an androgen receptor modulator
US10668156B2 (en) 2012-06-22 2020-06-02 Basf Se Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers
MX2015002430A (es) * 2012-08-24 2015-06-22 Dow Global Technologies Llc Acetato-succinatos de hidroxialquilmetilcelulosa.
JP6404217B2 (ja) 2012-09-11 2018-10-10 メディベイション プロステイト セラピューティクス エルエルシー エンザルタミドの製剤
US9977033B2 (en) 2012-09-11 2018-05-22 The Board Of Regents Of The University Of Texas System Methods for assessing cancer recurrence
NZ744456A (en) * 2012-09-26 2019-09-27 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
PL2945628T3 (pl) 2013-01-15 2020-09-21 Aragon Pharmaceuticals, Inc. Modulator receptorów androgenowych w skojarzeniu z octanem abirateronu i prednizonem do leczenia nowotworu stercza
WO2014114575A1 (en) 2013-01-22 2014-07-31 F. Hoffmann-La Roche Ag Pharmaceutical composition with improved bioavailability
US20140287039A1 (en) 2013-03-15 2014-09-25 Iceutica Inc. Abiraterone Acetate Formulation
WO2014167428A2 (en) 2013-04-10 2014-10-16 Shilpa Medicare Limited Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide
CN105636594A (zh) 2013-08-12 2016-06-01 托凯药业股份有限公司 使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物
US9566280B2 (en) 2014-01-28 2017-02-14 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
WO2015118015A1 (en) * 2014-02-05 2015-08-13 Lek Pharmaceuticals D.D. Solid pharmaceutical compositions of androgen receptor antagonists
TWI803187B (zh) 2014-08-08 2023-05-21 日商中外製藥股份有限公司 包含４環性化合物的非晶質體之固體分散體及製劑
HUE054935T2 (hu) 2014-12-05 2021-10-28 Aragon Pharmaceuticals Inc Rákellenes készítmények
LT3226842T (lt) 2014-12-05 2021-03-25 Aragon Pharmaceuticals, Inc. Priešvėžinės kompozicijos
SG11201704267VA (en) * 2014-12-05 2017-06-29 Aragon Pharmaceuticals Inc Anticancer compositions
CA3024872A1 (en) 2016-06-03 2017-12-07 Aragon Pharmaceuticals, Inc. Anticancer compositions
EP3812378A4 (en) 2018-06-20 2021-04-28 Crystal Pharmaceutical (Suzhou) Co., Ltd. CRYSTALLINE FORMS OF RNA-509, CORRESPONDING METHOD OF PREPARATION AND ASSOCIATED USE
EP3811932A1 (en) 2019-10-22 2021-04-28 Zentiva K.S. Dosage form of apalutamide

Also Published As

Publication number Publication date
EA201791222A1 (ru) 2017-09-29
TW201630592A (zh) 2016-09-01
MD3226841T2 (ro) 2025-06-30
EP3226841B1 (en) 2024-10-09
KR20170086656A (ko) 2017-07-26
JP7174006B2 (ja) 2022-11-17
EP3226841A1 (en) 2017-10-11
TWI754258B (zh) 2022-02-01
HRP20241719T1 (hr) 2025-02-14
UA120950C2 (uk) 2020-03-10
JP2017536398A (ja) 2017-12-07
JP6937692B2 (ja) 2021-09-22
AU2015358490A1 (en) 2017-06-08
MX387933B (es) 2025-03-19
CN106999431A (zh) 2017-08-01
SG11201704267VA (en) 2017-06-29
EP4494636A3 (en) 2025-04-30
IL252323A0 (en) 2017-07-31
IL279833B (en) 2022-03-01
TW202031248A (zh) 2020-09-01
CA2969656A1 (en) 2016-06-09
HUE069689T2 (hu) 2025-04-28
CO2017005572A2 (es) 2017-09-20
NZ731963A (en) 2024-03-22
AU2021201979B2 (en) 2023-02-02
US12303493B2 (en) 2025-05-20
BR112017011788A2 (pt) 2017-12-26
CN114886852A (zh) 2022-08-12
AR102926A1 (es) 2017-04-05
AU2015358490B2 (en) 2021-04-08
KR102348320B1 (ko) 2022-01-10
US20170360754A1 (en) 2017-12-21
MA41107A (fr) 2017-10-10
TWI702966B (zh) 2020-09-01
MA41107B1 (fr) 2025-01-31
PL3226841T3 (pl) 2025-03-03
CL2017001371A1 (es) 2018-01-05
CR20170216A (es) 2017-08-30
NZ770528A (en) 2024-03-22
WO2016090098A1 (en) 2016-06-09
RS66323B1 (sr) 2025-01-31
CN106999431B (zh) 2022-03-04
IL279833A (en) 2021-01-31
EP3226841C0 (en) 2024-10-09
JP2020143069A (ja) 2020-09-10
ES2996833T3 (en) 2025-02-13
AU2021201979A1 (en) 2021-04-29
US20230233529A1 (en) 2023-07-27
AU2023202710A1 (en) 2023-05-18
EP4494636A2 (en) 2025-01-22
PH12017500964A1 (en) 2017-10-18
IL252323B (en) 2021-04-29
SMT202400518T1 (it) 2025-01-14
MX2017007203A (es) 2017-08-28
US20240293374A1 (en) 2024-09-05
MX2021013965A (es) 2022-01-04

Similar Documents

Publication Publication Date Title
KR102348320B1 (ko) 항암 조성물
US20240293321A1 (en) Anticancer compositions
HK40078336A (en) Anticancer compositions
HK40055486A (en) Anticancer compositions
HK1241764B (en) Anticancer compositions
HK1241764A1 (en) Anticancer compositions
HK1241758A1 (en) Anticancer compositions
EA043321B1 (ru) Противораковая композиция

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20201209

Application number text: 1020177018239

Filing date: 20170630

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210107

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210305

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20211021

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210305

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I